Phaseline

Companies › Seattle Project

Seattle Project: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 2; Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GRT-C901
Patient-specific neoantigen cancer vaccine (viral-vectored)
–Phase 2Colorectal NeoplasmsMar 2027
GRT-R902
Patient-specific neoantigen cancer vaccine boost
–Phase 2Colorectal NeoplasmsMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05141721GRT-C901Phase 2Colorectal NeoplasmsOncologyMar 2027
NCT05141721GRT-R902Phase 2Colorectal NeoplasmsOncologyMar 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

iOnctura Toray Industries SynerGene Therapeutics Lyvgen Biopharma Holdings Imvax

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.